Page 1762 - Hematology_ Basic Principles and Practice ( PDFDrive )

1566 Part IX Cell-Based Therapies

REFERENCES
Cryobiology and Fitness of Thawed MSC Cellular Pharmaceuticals
1. Friedenstein AJ, Chailakhyan RK, Latsinik NV, et al: Stromal cells
Mesenchymal stromal cells (MSCs) from either a marrow or adipose
source, autologous, or of random donor origin are being investigated responsible for transferring the microenvironment of the hemopoietic
in a large number of clinical trials as a cellular pharmaceutical for tissues. Cloning in vitro and retransplantation in vivo. Transplantation
treatment of immune disorders such as Crohn disease, systemic lupus 17:331, 1974. PMID 4150881. 414.
erythematous, multiple sclerosis, graft-versus-host disease, and others. 2. Caplan AI: Mesenchymal stem cells. J Orthop Res 9:641–650, 1991.
Most typically, a polyclonal pool of ex vivo culture-expanded cells is PMID 1870029. 412.
cryopreserved and banked for later use. Human subjects subsequently 3. Prockop DJ: Marrow stromal cells as stem cells for nonhematopoietic
receive an intravenous transfusion of thawed MSCs that were retrieved tissues. Science 276:71–74, 1997. PMID 9082988. 415.
directly from cryostorage no more than a few hours beforehand. It is 4. Horwitz EM, Prockop DJ, Fitzpatrick LA, et al: Transplantability and
assumed that viable, immediate post-thaw MSCs deploy the same bio-
chemical, homing, and immunomodulatory features as their pre-freeze therapeutic effects of bone marrow-derived mesenchymal cells in chil-
counterparts. This assumption may be erroneous and may provide, in dren with osteogenesis imperfecta. Nat Med 5:309–313, 1999. PMID
part, an explanation for the discrepancy between preclinical animal 10086387. 423.
models of MSC effectiveness and negative outcomes of prospective 5. Horwitz EM, Gordon PL, Koo WK, et al: Isolated allogeneic bone
randomized clinical trials. In contrast to what is done in human trials, marrow-derived mesenchymal cells engraft and stimulate growth in
virtually all published preclinical work in mice reports the effect of live, children with osteogenesis imperfecta: Implications for cell therapy of
metabolically fit MSCs. It has been shown that MSCs deploy a heat bone. Proc Natl Acad Sci USA 99:8932–8937, 2002. PMID 12084934.
shock response immediately post-thaw, as well as trigger an instant 424124401.
blood-mediated inflammatory reaction (IBMIR). These acquired MSC 6. Lazarus HM, Haynesworth SE, Gerson SL, et al: Ex vivo expansion
pysiologic anomalies are associated with a profound alteration of their
in vivo distribution and fate post-intravenous transfusion, markedly and subsequent infusion of human bone marrow-derived stromal
blunts their ability to exert immunomodulatory effects, and renders progenitor cells (mesenchymal progenitor cells): implications for thera-
them susceptible to complement-mediated lysis. This fundamental peutic use. Bone Marrow Transplant 16:557–564, 1995. PMID 8528172.
discrepancy in the handling of MSCs at time of adoptive transfer to 410.
animal models and human subjects provides an explanation for the 7. Le Blanc K, Rasmusson I, Sundberg B, et al: Treatment of severe acute
apparent paradox of MSC utility for mice but not in men. A funda- graft-versus-host disease with third party haploidentical mesenchymal
mental truism applicable to most cell-based therapies may be that stem cells. Lancet 363:1439–1441, 2004. PMID 15121408. 134.
metabolically fit, undamaged cells are distinct than a thawed product 8. Baron F, Storb R: Mesenchymal stromal cells: a new tool against graft-
as a cellular pharmaceutical.
versus-host disease? Biol Blood Marrow Transplant 18:822–840, 2012.
PMID 21963621. 4293310956.
9. Galipeau J: The mesenchymal stromal cells dilemma–does a negative
phase III trial of random donor mesenchymal stromal cells in steroid-
resistant graft-versus-host disease represent a death knell or a bump in
MSC Phenotype: Does Form Predict Function? the road? Cytotherapy 15:2–8, 2013. PMID 23260081. 220.
10. Kfoury Y, Scadden DT: Mesenchymal cell contributions to the stem cell
Mesenchymal stromal cells (MSCs) are a cellular product that is ex niche. Cell Stem Cell 16:239–253, 2015. PMID 25748931. 437.
vivo culture expanded using established, clinically applicable methods. 11. Bianco P, Cao X, Frenette PS, et al: The meaning, the sense and the
According to the International Society of Cell Therapy guidelines, MSCs significance: translating the science of mesenchymal stem cells into
must be plastic adherent when maintained in standard culture condi- medicine. Nat Med 19:35–42, 2013. PMID 23296015. 4313998103.
tions, express major histocompatibility complex class I molecules as 12. Dominici M, Le Blanc K, Mueller I, et al: Minimal criteria for defining
well as surface CD105, CD90, CD73, and CD44; lack expression of
hematopoietic markers CD45, CD34, CD11b, and CD19; and retain the multipotent mesenchymal stromal cells. The International Society for
ability to differentiate to osteoblasts, adipocytes, and chondroblasts in Cellular Therapy position statement. Cytotherapy 8:315–317, 2006.
vitro (Table 99.1). Although useful in confirming identity, these markers PMID 16923606. 150.
have virtually no utility in predicting function or immunosuppressive 13. Krampera M, Galipeau J, Shi Y, et al: Immunological characterization
potency. Indeed, these markers are remarkably uniform in their expres- of multipotent mesenchymal stromal cells–The International Society for
sion among different individual donors, and the assumption is that Cellular Therapy (ISCT) working proposal. Cytotherapy 15:1054–1061,
marrow MSCs are equipotent independent of donor fitness, age, or 2013. PMID 23602578. 250.
biology. This assumption may be flawed, especially when interrogating 14. Bourin P, Bunnell BA, Casteilla L, et al: Stromal cells from the adipose
the immune plasticity of MSCs derived from otherwise indistinguish- tissue-derived stromal vascular fraction and culture expanded adipose
able donor source. It is now well established that cytokine licensing
of human MSCs with interferon-γ (IFN-γ) markedly potentiates their tissue-derived stromal/stem cells: a joint statement of the International
immunosuppressive properties in vitro, and murine data support the Federation for Adipose Therapeutics and Science (IFATS) and the Inter-
theory that in vivo IFN-γ responsiveness is mandatory for their suppres- national Society for Cellular Therapy (ISCT). Cytotherapy 15:641–648,
sion function. Utilizing IFN-γ-induced IDO upregulation as a surrogate 2013. PMID 23570660. 4273979435.
marker of suppressor function, it has been shown that there are 15. Bernardo ME, Fibbe WE: Mesenchymal stromal cells: sensors and
substantial differences in the magnitude of IDO responsiveness arising switchers of inflammation. Cell Stem Cell 13:392–402, 2013. PMID
from IFN-γ activation of otherwise indistinguishable MSC preparations 24094322. 242.
from normal human donors and that the magnitude of IDO response 16. Le Blanc K, Mougiakakos D: Multipotent mesenchymal stromal cells
among individual donors correlates with MSC veto function. This and the innate immune system. Nat Rev Immunol 12:383–396, 2012.
observation strongly suggests that IFN-γ responsiveness is not uniform
among human subjects and that MSCs derived from low IDO inducers PMID 22531326. 128.
may be substantially less potent than cells derived from high inducers. 17. Ren G, Zhang L, Zhao X, et al: Mesenchymal stem cell-mediated
Clinical studies exploiting mass-produced MSCs on an industrial scale immunosuppression occurs via concerted action of chemokines
where thousands of doses derived from a few donors are used to treat a and nitric oxide. Cell Stem Cell 2:141–150, 2008. PMID 18371435.
multiplicity of subjects, which may lead to an unfavorable potency bias. 153.
For example, if many patients receive MSCs derived from a normal 18. Nemeth K, Leelahavanichkul A, Yuen PS, et al: Bone marrow stromal
volunteer who happens to be a low IFN-γ responder, the outcome cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming
may be not as good as if patients had received cells from a high IFN-γ of host macrophages to increase their interleukin-10 production. Nat
responder donor. Mechanistically-defined MSC potency profiling may Med 15:42–49, 2009. PMID 19098906. 4352706487.
provide scientific rationale for selection of volunteer donors whose MSC
deploys the greatest veto function and avoid the pitfalls of less potent 19. Ren G, Su J, Zhang L, et al: Species variation in the mechanisms of
MSC products in subjects participating in pivotal clinical trials. mesenchymal stem cell-mediated immunosuppression. Stem Cells
27:1954–1962, 2009. PMID 19544427. 152.